Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities

- Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11

Read more at globenewswire.com